Patents
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
06/2005
06/02/2005US20050119458 Transport protein for use in identifying modulator for prevention and treatment of cell proliferative, skin and psychological disorders; anticonvulsants; insecticides; pesticides; anthelmintics
06/02/2005US20050119457 Human proteins
06/02/2005US20050119456 and a monoclonal, humanized, or single-chain antibody specific for the C21 polypeptide; gene overexpression in mouse hematopoeitic cells alters myeloid development and in 3T3 fibroblasts, increases apoptosis resistance
06/02/2005US20050119454 Biosynthesis of amino acid sequences; rearrangement of peptides; schizophrenia; Parkinson's disease; analgesics; central nervous system disorders
06/02/2005US20050119215 Regulator genes of angiogenesis, pharmaceutical preparations containing them and their applications
06/02/2005US20050119210 Using genes encoding transmembrane protein as markers; targets for cancer therapy; drug screening
06/02/2005US20050119209 Compositions and methods for the treatment and diagnosis of immune disorders
06/02/2005US20050119208 Composition and method for treating lupus nephritis
06/02/2005US20050119207 Administering an agents, such as antibody,which prevents gene expresion; analgesics; anesthetics
06/02/2005US20050119206 Cg8327, cg10823, cg18418, cg15862, cg3768, cg11447 and cg16750 homologous proteins involved in the regulation of energy homeostasis
06/02/2005US20050119204 Osteopontin-related compositions and methods
06/02/2005US20050119198 Novel target to inhibit angiogenesis
06/02/2005US20050119187 Anti-fibril peptides
06/02/2005US20050119185 Anticancer agents ; leukemia
06/02/2005US20050119184 Immunoregulator
06/02/2005US20050119182 Bioassay; detect compound as antigonist; antiserotonine agents
06/02/2005US20050119181 Hydrophobically-modified protein compositions and methods
06/02/2005US20050119178 Insulinotropic hormone derivatives and uses thereof
06/02/2005US20050119173 Novel potassium-dependent sodium-calcium exchanger
06/02/2005US20050119172 Purity, genetic engineered human serum albumin for Factor viii
06/02/2005US20050119171 Forsenic analysis; medical diagnosis; chromosome markers
06/02/2005US20050119166 Complex of cytotoxic agent with aoligopeptide; amino acid sequence proteolytic splitting prostate specific antigen; prostate cancer; benign prostatic hyperplasia
06/02/2005US20050119165 Vascular endothelial growth factor dimers
06/02/2005US20050118729 Microarrays of cellulose binding chimeric proteins and methods of use thereof
06/02/2005US20050118719 Expression vector comprising C1-regulated promoter sequence for use as an enhanced tool in transfer of heterologous gene sequences into cells
06/02/2005US20050118717 delivering to microtubules a microtubule binding substance, such as taxol, that is coupled to a herpes simplex virus 1 VP22 protein; may be used pharmaceutically to retard or arrest cell division of cells such as neoplastic cells or protozoal parasite cells in vitro or in vivo.
06/02/2005US20050118690 Love variant regulator molecules
06/02/2005US20050118687 Methods of synthesizing polynucleotide via reverse translation from protein and oligonucleotide used in this method
06/02/2005US20050118685 Enhanced secretion of a polypeptide by a microorganism
06/02/2005US20050118684 Recombinant antihemophilic factor for use as tool in treatment hemophilia
06/02/2005US20050118683 Method for producing a polypeptide
06/02/2005US20050118682 Using transgenic animal to prepare osteoclastogenesis inhibitory factor (OCIF) for use in treatment of osteoporosis
06/02/2005US20050118681 Transcription factor for use as regulatory tool in expression of musculin; treatment and prevention of myogenic cancers
06/02/2005US20050118680 Human chemotactic protein
06/02/2005US20050118679 Novel metalloproteinases
06/02/2005US20050118678 Modified polypeptide comprising amphipathic alpha -helical structure for use in prevention and treatment of infection and cell proliferative disorders
06/02/2005US20050118677 CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection
06/02/2005US20050118676 Gene therapy vectors having reduced immunogenicity
06/02/2005US20050118675 Heptahelix receptor and its use as leukotriene B4 receptor
06/02/2005US20050118672 Using peptide: N-Glycosidase F (PNGase-F) to generate glycopeptide with uniform glycosylation patterns
06/02/2005US20050118668 Non-radioactive label fluorophore covalently bonded to a modified tyrosine residue
06/02/2005US20050118661 Fibronectin variants and screening methods
06/02/2005US20050118659 Bacterial polypeptide for use in diagnosis, prevention and treatment of microbial infection
06/02/2005US20050118649 Monitoring protein translocation into preferential cellular compartment via reporter expression of fluorescent protein fusion
06/02/2005US20050118645 Prion specific immunogllobulin for detection, diagnosis and prevention of spongiform encephalopathies; immunotherapy
06/02/2005US20050118643 Specific binding agents to hepatocyte growth factor
06/02/2005US20050118641 Quantitative analysis; for stabilization of insulin forms
06/02/2005US20050118639 Using fluorescent protein reporting to identify interaction between receptor binding agent and orphan receptor; immunoassay
06/02/2005US20050118638 Using thyrotrophin (TSH) receptor as diagnostic tool in detection of autoimmune diseases; competive binding assay
06/02/2005US20050118635 Using cytoskeletal membrane protein concentration as diagnostic indicator of cell proliferative disorders; antitumor agents
06/02/2005US20050118629 antibody to polypeptide containing a fragment capable of binding to and inducing apoptosis in a carcinoma cell; Tumor Necrosis Factor Related ligand or "TRELL", a polypeptide which is a member of the Tumor Necrosis Factor Family
06/02/2005US20050118626 Novel human collagen proteins and polynucleotides encoding the same
06/02/2005US20050118623 Single nucleotide polymorphism analysis of highly polymorphic target sequences
06/02/2005US20050118617 Solid phase synthesis; microarrays
06/02/2005US20050118615 Chordin-like homologs
06/02/2005US20050118614 Compositions and methods using eukaryotic Rad5
06/02/2005US20050118604 Modulators of angiogenesis and tumorigenesis
06/02/2005US20050118598 Polypeptides derived from fibrinogen; modified by cyclization; antiangiogenic; transgenic cells, animals
06/02/2005US20050118597 Peptide II
06/02/2005US20050118594 Enzymes
06/02/2005US20050118592 Using allelic variation aristaless homeobox gene (ARX) as diagnostic tool in detection of convulsive and learning disorders
06/02/2005US20050118588 Nucleotide sequences coding neuroligin for use in the diagnosis, prevention and treatment of mental and psychological disorders
06/02/2005US20050118586 Expression vector comprising nucleotide sequences coding heterologous polypeptide for use in forensic analysis as chromosome, tissue, cell and organelle specific markers
06/02/2005US20050118583 Novel genetic products of ashbya gossypii, associated with the mechanisms of signal transduction and especially with the improvement of vitamin b2 production
06/02/2005US20050118582 Nucleoprotein for use as tool in treatment, diagnosis and prevention of infection, cell proliferative, neurological, developmental, autoimmune and inflammatory disorders
06/02/2005US20050118581 Novel brain expressed gene and protein associated with bipolar disorder
06/02/2005US20050118579 Using allelic variation in canalicular multispecific organic anion transporter (cMOAT) gene as diagnostic tool in detection of liver and bile duct disorders
06/02/2005US20050118575 Immune cell polypeptide for use in diagnosis and treatment of cell proliferative disorders
06/02/2005US20050118573 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses
06/02/2005US20050118571 Nucleic acids comprising viral genome and ribozyme sequences for use in animal models system for designing treatments for prevention of hepatitis viral infection
06/02/2005US20050118569 Genetic engineering of streptavidin-binding peptide tagged single-chain variable fragment antibody to venezuelan equine encephalitis virus
06/02/2005US20050118199 Process for covalently conjugating polysaccharides to microspheres or biomolecules
06/02/2005US20050118195 Virus causing respiratory tract illness in susceptible mammals
06/02/2005US20050118191 Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
06/02/2005US20050118190 Staphylococcus antigen and vaccine
06/02/2005US20050118189 Mutant Hin47 protein with decreased protease activity, and a high molecular weight protein of a strain of non-typeable Haemophilus influenzae; may be combined with diphtheria or tetanus toxoids, pertussis antigens or non-virulent poliovirus; immunization; otitis media
06/02/2005US20050118184 Compositions and methods for enhancing the immunogenicity of antigens
06/02/2005US20050118179 Prostate apoptosis response-4 (Par-4) mutants which cause apoptosis in sensitive cancer cells; kits, vectors, and polypeptides
06/02/2005US20050118178 Use of t-cell immune response cdna7 (tirc7) in angiogenic and anti-angiogenic therapy
06/02/2005US20050118176 Inhibiting binding of interleukin-4 (IL-4) to an IL-4 Receptor; suppressing an IL-4-dependent immune or inflammatory response in a mammal
06/02/2005US20050118170 Use of discoidin domain receptor 1 (ddr1) and agents that affect the ddr1/collagen pathway
06/02/2005US20050118166 Inhibiting activation by CD40 ligand (CD40L) of cells bearing CD40 on the cell surface, other than B cells, by contacting with an agent that inhibits the interaction between CD40L and the cells; treating autoimmune diseases
06/02/2005US20050118160 Inhibits delayed vascular rejection; makes organs less vulnerable to rejection after transplantation
06/02/2005US20050118154 Antitumor effect of mutant Bik
06/02/2005US20050118148 Compositions and methods related to mammalian Maf-A
06/02/2005US20050118141 Transplantable lung carcinoma xenograft useful in experimental models of carcinoma in order to dissect out the molecular basis of the phenotype; the model of carcinoma can be used to identify molecular targets, assess the efficacy of theraputic agents
06/02/2005US20050118139 Canine papillomavirus E genes are codon-optimized to enhance expression in host cells; the vector is an adenovirus vector or a plasmid vector, and the genes are from a human papillomavirus serotype; prevention and prophylaxis
06/02/2005US20050118136 Polyaspartic acid or polyglutamic acid end capped by oligopeptides of various amino acid sequences; improved pharmacokinetics, bioavailability and water solubility of conjugated drugs
06/02/2005US20050118117 Methods for identifying risk of melanoma and treatments thereof
06/02/2005US20050118114 Pulmonary insulin crystals
06/02/2005US20050118099 Thiol-mediated drug attachment to targeting peptides
06/02/2005DE4139840B4 Antigen-Zubereitung zum Nachweis von H. pylori Antigen preparation for the detection of H. pylori
06/02/2005CA2747871A1 Compositions and methods for the treatment of tumor of hematopoietic origin
06/02/2005CA2547087A1 Ice recrystallisation inhibition protein or antifreeze proteins from deschampsia, lolium and festuca species of grass
06/02/2005CA2547079A1 Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
06/02/2005CA2546873A1 Surface-located campylobacter jejuni polypeptides
06/02/2005CA2546860A1 Ocular tissue modification
06/02/2005CA2546840A1 Immunization against chlamydia infection
06/02/2005CA2546836A1 Immunization against chlamydia infection
06/02/2005CA2546794A1 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients